KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Depreciation & Amortization (CF) (2017 - 2025)

Guardant Health (GH) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 3.86% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.7 million through Dec 2025, down 6.25% year-over-year, with the annual reading at $39.7 million for FY2025, 6.25% down from the prior year.
  • Depreciation & Amortization (CF) hit $10.0 million in Q4 2025 for Guardant Health, up from $9.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $11.0 million in Q3 2023 to a low of $5.0 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $9.2 million across 5 years, with a median of $10.1 million in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 76.89% in 2022 and later dropped 11.23% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $6.1 million in 2021, then soared by 66.98% to $10.2 million in 2022, then grew by 6.87% to $10.9 million in 2023, then dropped by 3.81% to $10.5 million in 2024, then fell by 3.86% to $10.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for GH at $10.0 million in Q4 2025, $9.4 million in Q3 2025, and $10.0 million in Q2 2025.